Literature DB >> 25692535

Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Peng He1, Yening Zou, Zhongyu Hu.   

Abstract

In the past few decades, hundreds of materials have been tried as adjuvant; however, only aluminum-based adjuvants continue to be used widely in the world. Aluminum hydroxide, aluminum phosphate and alum constitute the main forms of aluminum used as adjuvants. Among these, aluminum hydroxide is the most commonly used chemical as adjuvant. In spite of its wide spread use, surprisingly, the mechanism of how aluminum hydroxide-based adjuvants exert their beneficial effects is still not fully understood. Current explanations for the mode of action of aluminum hydroxide-based adjuvants include, among others, the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway. These collectively galvanize innate as well as acquired immune responses and activate the complement system. Factors that have a profound influence on responses evoked by aluminum hydroxide-based adjuvant applications include adsorption rate, strength of the adsorption, size and uniformity of aluminum hydroxide particles, dosage of adjuvant, and the nature of antigens. Although vaccines containing aluminum hydroxide-based adjuvants are beneficial, sometimes they cause adverse reactions. Further, these vaccines cannot be stored frozen. Until recently, aluminum hydroxide-based adjuvants were known to preferentially prime Th2-type immune responses. However, results of more recent studies show that depending on the vaccination route, aluminum hydroxide-based adjuvants can enhance both Th1 as well as Th2 cellular responses. Advances in systems biology have opened up new avenues for studying mechanisms of aluminum hydroxide-based adjuvants. These will assist in scaling new frontiers in aluminum hydroxide-based adjuvant research that include improvement of formulations, use of nanoparticles of aluminum hydroxide and development of composite adjuvants.

Entities:  

Keywords:  adjuvants; aluminum compounds; aluminum hydroxide; aluminum phosphate; immune response; inflammasomes; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25692535      PMCID: PMC4514166          DOI: 10.1080/21645515.2014.1004026

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  99 in total

1.  Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.

Authors:  Bethany Hansen; Anna Sokolovska; Harm HogenEsch; Stanley L Hem
Journal:  Vaccine       Date:  2007-07-16       Impact factor: 3.641

2.  Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity.

Authors:  D Diminsky; R Schirmbeck; J Reimann; Y Barenholz
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

3.  CpG/Poly (I:C) mixed adjuvant priming enhances the immunogenicity of a DNA vaccine against eastern equine encephalitis virus in mice.

Authors:  JinZhu Ma; HuaLei Wang; XueXing Zheng; XiangHong Xue; BeiYan Wang; HongXia Wu; Kun Zhang; ShengTao Fan; TieCheng Wang; Nan Li; YongKun Zhao; YuWei Gao; SongTao Yang; XianZhu Xia
Journal:  Int Immunopharmacol       Date:  2014-01-17       Impact factor: 4.932

4.  The immunobiology of aluminium adjuvants: how do they really work?

Authors:  Christopher Exley; Peter Siesjö; Håkan Eriksson
Journal:  Trends Immunol       Date:  2010-02-10       Impact factor: 16.687

5.  In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid.

Authors:  R K Gupta; A C Chang; P Griffin; R Rivera; G R Siber
Journal:  Vaccine       Date:  1996-10       Impact factor: 3.641

6.  Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Authors:  Andreas Wack; Barbara C Baudner; Anne K Hilbert; Ilaria Manini; Sandra Nuti; Simona Tavarini; Hanno Scheffczik; Mildred Ugozzoli; Manmohan Singh; Jina Kazzaz; Emanuele Montomoli; Giuseppe Del Giudice; Rino Rappuoli; Derek T O'Hagan
Journal:  Vaccine       Date:  2007-12-07       Impact factor: 3.641

7.  Adsorption of phosphate by aluminum hydroxycarbonate.

Authors:  J C Liu; J R Feldkamp; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

8.  Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles.

Authors:  J Kreuter; E Liehl
Journal:  J Pharm Sci       Date:  1981-04       Impact factor: 3.534

9.  A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome.

Authors:  Christopher Exley; Louise Swarbrick; Rhomain K Gherardi; Francois-Jérôme Authier
Journal:  Med Hypotheses       Date:  2008-11-11       Impact factor: 1.538

10.  Antigen depot is not required for alum adjuvanticity.

Authors:  Sharon Hutchison; Robert A Benson; Vivienne B Gibson; Abigail H Pollock; Paul Garside; James M Brewer
Journal:  FASEB J       Date:  2011-11-21       Impact factor: 5.191

View more
  85 in total

1.  Improving vaccines against Streptococcus pneumoniae using synthetic glycans.

Authors:  Paulina Kaplonek; Naeem Khan; Katrin Reppe; Benjamin Schumann; Madhu Emmadi; Marilda P Lisboa; Fei-Fei Xu; Adam D J Calow; Sharavathi G Parameswarappa; Martin Witzenrath; Claney L Pereira; Peter H Seeberger
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-07       Impact factor: 11.205

Review 2.  [Composition and mode of action of adjuvants in licensed viral vaccines].

Authors:  Ralf Wagner; Eberhard Hildt
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

Review 3.  Neonatal Vaccination: Challenges and Intervention Strategies.

Authors:  Matthew C Morris; Naveen Surendran
Journal:  Neonatology       Date:  2016-01-13       Impact factor: 4.035

4.  Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Xu Li; Amber N Taylor; Yan-Chun Shi; Zhengrong Cui
Journal:  Vaccine       Date:  2016-05-05       Impact factor: 3.641

5.  Aluminum (Oxy)Hydroxide Nanosticks Synthesized in Bicontinuous Reverse Microemulsion Have Potent Vaccine Adjuvant Activity.

Authors:  Xu Li; Stephanie Hufnagel; Haiyue Xu; Solange A Valdes; Sachin G Thakkar; Zhengrong Cui; Hugo Celio
Journal:  ACS Appl Mater Interfaces       Date:  2017-06-29       Impact factor: 9.229

6.  NLRP3 inflammasome activation by Foot-and-mouth disease virus infection mainly induced by viral RNA and non-structural protein 2B.

Authors:  Xiaoying Zhi; Yun Zhang; Shiqi Sun; Zhihui Zhang; Hu Dong; Xin Luo; Yanquan Wei; Zengjun Lu; Yongxi Dou; Run Wu; Zhengfan Jiang; Changjiang Weng; Ho Seong Seo; Huichen Guo
Journal:  RNA Biol       Date:  2019-12-15       Impact factor: 4.652

7.  Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response.

Authors:  Inés Herrero-Fernández; Yolanda M Pacheco; Ezequiel Ruiz-Mateos; Manuel Leal; Miguel Genebat; María Del Mar Rodriguez-Méndez; María Del Carmen Lozano; María José Polaino; Isaac Rosado-Sánchez; Laura Tarancón-Diez; María Ángeles Muñoz-Fernández
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris.

Authors:  Zhijian Yang; Fan Gao; Xiaoliang Wang; Likang Shi; Zheng Zhou; Yuanxiang Jiang; Xinxing Ma; Chao Zhang; Chenliang Zhou; Xianfang Zeng; Ge Liu; Jiang Fan; Qunying Mao; Li Shi
Journal:  Hum Vaccin Immunother       Date:  2019-08-15       Impact factor: 3.452

9.  The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells.

Authors:  Marlena M Westcott; Elene A Clemens; Beth C Holbrook; S Bruce King; Martha A Alexander-Miller
Journal:  Vaccine       Date:  2018-02-21       Impact factor: 3.641

10.  Efficient antigen cross-presentation through coating conventional aluminum adjuvant particles with PEI.

Authors:  Hongyan Ren; Yongbin Mou; Lin Lin; Lixin Wang; Hongming Hu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.